International Journal of Pharmacy and Analytical Research (IJPAR)

IJPAR |Vol.13 | Issue 3 | Jul - Sept -2024

www.ijpar.com

ISSN: 2320-2831

DOI : https://doi.org/10.61096/ijpar.v13.iss3.2024.392-398

Review

Role of Artificial Intelligence (AI) Tools and Machine Learning (ML) in Clinical Trials for FDA Approval of Pharmaceutical Drugs: A Comprehensive Review

Rahul Swamy Tirunagari[1]

*[1]*Griffith College Cork, Ireland.*

*Author for Correspondence: Rahul Swamy Tirunagari
Email: rahulswamyt@gmail.com

Published on: 02 Sep 2024

Published by:
DrSriram Publications

Abstract

Over the past few decades, India's pharmaceutical sector has seen major technological innovations in drug development. India now holds a major place in the world for pharmaceutical research and development as a result of these developments. The purpose of this abstract is to give a general overview of some significant technological advancements in the Indian pharmaceutical sector, with a focus on drug development. The growing use of artificial intelligence (AI) and machine learning (ML) algorithms in several phases of drug research and development is one noteworthy advance. These technologies make things quicker and more precise. furthermore, the production of drug and development of drug to the unique techniques. Proteomics and genomics developments have also enabled innovative drugs development methods by enabling the production of drug customized or drug combinational to the unique profiles of each subject. India is becoming a major participant in the global pharmaceutical scene thanks to technical developments in drug discovery, which have also fuelled advances in safety, personalized medicine, and therapeutic efficacy. Yet issues like infrastructure development of drugs and Ethical and safety and AI and ML Validation and Government and Regularity authority Guidance and regulatory compliance still exist, underscoring the necessity of ongoing funding and cooperation in the pharmaceutical industry. This research work aims to study the AI and ML approaches in clinical trials for a FDA approval. The objectives are studied by conducting a interview with the participants from the industry personnel. Key findings from the research are that training and awareness are required in the industry about the AI involvement in the clinical trials. there should be a regulatory compliance maintained to achieve smooth and diligent protocol for clinical trials with AI for FDA approvals.

Keywords: Artificial intelligence, drug discovery, clinical trials, interviews, pharmaceutical industry, data analysis.

INTRODUCTION

A scientific discovery needs time and work to be developed into a pharmaceutical that is marketable. It takes a minimum of 12 to 15 years from invention to approved treatment[1]. Drug development often goes through several stages.

Discovery and Development

Potential therapeutic candidates are found by researchers using techniques like chemical library screening and pathophysiology-based molecular design. Figure 1 delineates the many phases involved in drug discovery.

Preclinical Research

Following identification of the drug candidates, preclinical research is carried out in lab settings utilizing animal models and cell cultures to evaluate the drug candidates' pharmacokinetics, safety, and effectiveness[2].

Investigational New Drug (IND) Application

If the preclinical investigations yield encouraging findings, an IND will be submitted to regulatory bodies such as the FDA, requesting authorization to begin human clinical trials.[2]



Fig 1: Stages of drug discovery to FDA approval[3].

Clinical Trials: Clinical trials consist of three phases[4]:

a. Phase 1: small-scale studies carried out in fit participants to assess pharmacokinetics, dose, and safety.

b. Phase 2: trials with a broader patient population with the intended illness in order to gauge effectiveness and further analyse safety.

c. Phase 3: large-scale studies carried out to verify effectiveness, track adverse effects, and contrast the novel medication with already available therapies. (Gupta, 2011)

New Drug Application (NDA) Submission

An NDA, which includes extensive information on the drug's safety and effectiveness, is submitted to regulatory bodies following the successful conclusion of clinical studies.

Regulatory Review

Regulatory bodies examine the NDA to ascertain whether the medication satisfies requirements for approval in terms of safety and effectiveness.

Approval and Post-Marketing Surveillance

Drugs can be advertised and sold to patients after they are approved. The safety and efficacy of the medication are continuously observed in real-world contexts through post-marketing surveillance.

Phase 4 Trials

Once approved, these studies might be carried out to learn more about the drug's long-term safety, effectiveness, and best usage.

Figure 2 shows how artificial intelligence is used and applied in drug development.



Fig 2: Artificial intelligence (AI) application in the pharmaceutical development process.

The results (Fig 2) and approaches of the many steps in the drug development process are explained. Additionally displayed are the uses of AI at every step of the drug development process[5].

The Role of Artificial Intelligence (AI) Tools and Machine Learning (ML) in Clinical Trials for FDA Approval of Pharmaceutical Drugs

The purpose of AI and ML technologies is to speed up the FDA approval process for pharmaceutical medications by improving several components of clinical trials in a unique way[6]. In order to better understand the possible advantages, difficulties, regulatory concerns, and future directions of AI and ML applications in clinical trials, this literature review critically analyzes the field's current state.

Artificial Intelligence (AI) and Machine Learning (ML) in Patient Cohort Selection

Patient cohort selection is one of the primary areas where AI and ML show great promise. Researchers are able to predict therapy responses, identify individuals with quantifiable clinical outcomes, and efficiently minimize population heterogeneity by utilizing AI algorithms. A vital part of this process is the identification of patients with certain features of interest through the use of electronic phenotyping, a discipline within health informatics[7]. New developments in machine learning (ML) techniques, including as deep learning (DL) and natural language processing (NLP), have demonstrated encouraging outcomes in managing challenging real-world scenarios and refining patient cohort selection tactics.

Predictive Enrichment and Prognostic Enrichment

In clinical trials, predictive enrichment and prognostic enrichment are made possible by AI and ML approaches, which makes it easier to identify patient subpopulations that are more likely to react to therapy[8]. In neurological illnesses, machine learning (ML) models, especially deep learning algorithms, have been used for prognostic enrichment. These models approximate important biomarkers and offer important insights into the course of the disease[9]. Modeling pharmacological effects and illness development in diseases like Alzheimer's disease, the Coalition Against Major Diseases (CAMD) is an example of a collaborative effort that has succeeded in enhancing clinical trial simulation (CTS) tools.

Assistance in Recruitment

Because clinical trials include complicated eligibility requirements and a lot of medical language, finding qualified participants for them can be difficult. Artificial Intelligence (AI) methods, such as natural language processing (NLP) and reasoning algorithms, provide workable answers by automatically evaluating electronic medical records (EMRs) and connecting patients with appropriate trials[10]. By increasing patient access to clinical trials and improving recruiting efficiency, these AI-based clinical trial matching systems have proven their efficacy in real-world situations.

Regulatory and Legal Considerations

The use of AI and ML in clinical trials may be advantageous, but there are still legal and regulatory obstacles to overcome. Careful attention is necessary to maintain compliance with legal frameworks like HIPAA and GDPR for issues connected to data protection, security, and the explainability of AI models (Hubert, 2024). Moreover, the FDA and other regulatory bodies emphasise the significance of strong validation and openness in algorithm development as they assess the safety and effectiveness of AI-driven technology.[11]

Patient Monitoring and Adherence

AI-enabled patient monitoring systems offer novel approaches to improving adherence to trial protocols and collecting reliable data points. Wearable sensors and ML algorithms enable real-time analysis of patient data, facilitating early detection of non-adherence and personalized interventions. Deep learning algorithms, coupled with image-based endpoint detection techniques, present opportunities for automating disease monitoring and reducing manual processing costs.[5]

A study by Aliper and team titled "Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi-Modal Artificial Intelligence" introduces inClinico, an AI platform designed to forecast phase II clinical trial results[12]. It highlights the significance of precise trial outcome predictions in enhancing drug development efficiency and guiding investment decisions. The platform integrates various data modalities, including omics, text, and trial design features, to generate[11].

inClinico comprises two main models: one focused on target selection and the other on trial design. The target model incorporates interactomic and transcriptomic data, while the trial design model considers enrollment numbers, patient demographics, and other trial specifics. Additionally, a meta-model combines predictions from both models to produce a final success probability for each trial.

Validation studies, including retrospective and quasi-prospective analyses, demonstrate the platform's effectiveness in predicting trial outcomes. The target model notably outperforms the trial design model. Prospective validation includes publicly forecasting outcomes for phase II trials, achieving a 79% accuracy rate for trials with reported results. The paper also explores using in Clinico for investment portfolio management, showing a 35% return on investment over nine months.

Overall, the study underscores the potential of AI in optimizing drug development pipelines and facilitating more informed investment decisions in the pharmaceutical industry[12]. However, further research is needed to refine AI models and enhance their predictive capabilities in drug development contexts.

2017 observed the start of a ground-breaking project called Accelerating Therapeutics for Opportunities in Medicine (ATOM) by the University of California, San Francisco (UCSF), Glaxo Smith Kline (GSK), Lawrence Livermore National Laboratory (LLNL), and the Frederick National Laboratory for Cancer Research (FNLCR). Using high-performance computation, shared biological data, and future biotechnologies, this partnership seeks to transform the process of finding cancer drugs. ATOM hopes to cut the length of time needed for drug discovery in half, from six years to only twelve months, by combining these resources.

ATOM's multidisciplinary approach combines modern science, technology, supercomputing simulations, data science, and artificial intelligence into a unified drug discovery platform. The consortium emphasizes open sharing of data and collaborative efforts to advance cancer therapeutics rapidly. GSK will contribute chemical and biological data, while LLNL will provide supercomputers and expertise in modeling and simulation. FNLCR brings scientific expertise in precision oncology, computational chemistry, and cancer biology, while UCSF offers its long-standing innovation in drug discovery and medicine.

This partnership underscores a collective commitment to accelerate the pace of drug discovery, improve patient outcomes, and advance global health initiatives.[13]

Future Directions

Looking ahead, the integration of AI tools and ML techniques in clinical trials is poised to revolutionize drug development processes. Future research endeavors should focus on addressing remaining challenges, including data interoperability, algorithm interpretability, and ethical considerations.[14] will be essential in driving innovation and ensuring the safe and efficient adoption of AI-driven technologies in pharmaceutical clinical trials. The Figure 3 discusses the AI involvement in clinical development.



Fig 3: Cases of artificial intelligence, computer vision, and machine learning in clinical development[6]

Conceptual framework

The conceptual framework for this research deals with the intersection of technological innovations, drug development processes, and FDA approval via clinical trials within the context of the Indian pharmaceutical industry. It is based on the understanding that technological advancements like AI and ML play a pivotal role in shaping the efficiency, safety, and success of drug development endeavours, particularly in obtaining regulatory approvals such as those from the FDA. The framework integrates key components such as research philosophy, approach, strategy, data collection, analysis, and implications to provide a comprehensive understanding of the pharmaceutical innovation in India.

This research adopts a comprehensive approach interviewing for diverse perspectives and objectives of stakeholders involved in drug development and FDA approval processes. Primary data is collected through interviews with key stakeholders, including pharmaceutical companies, regulatory agencies, clinical research organizations, healthcare professionals, and quality control advocacy groups.

Overall, the conceptual framework provides a structured approach for investigating the role of technological innovations in drug development and FDA approval via clinical trials in India, aiming to advance knowledge and inform practice in the pharmaceutical industry.



Fig 4: Conceptual framework

CONCLUSION

In conclusion, the utilization of AI tools and machine learning in clinical trials holds immense promise for accelerating the FDA approval of pharmaceutical drugs. By optimizing patient cohort selection, enhancing recruitment efficiency, and improving patient monitoring and applying AI tools, contribute to streamlining drug development processes and delivering innovative treatments to patients with successful clinical trials. However, addressing regulatory, legal, and ethical challenges remains imperative to realize the full potential of AI-driven innovations in the pharmaceutical industry.

REFERENCES

1. Gupta, S. Drug Discovery And Clinical Research, Jp Medical Ltd. 2011.
2. Deore, A. B., Dhumane, J. R., Wagh, R. Sonawane, R. The Stages Of Drug Discovery And Development Process. Asian Journal Of Pharmaceutical Research And Development, 2019; 7**,** 62-67.
3. Harrer, S., Shah, P., Antony, B. Hu, J. Artificial Intelligence For Clinical Trial Design. Trends In Pharmacological Sciences, 2019; 40**,** 577-591.
4. Mohs, R. C. Greig, N. H. Drug Discovery And Development: Role Of Basic Biological Research. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2017; 3**,** 651-657.
5. Mak, K.-K. & Pichika, M. R. Artificial Intelligence In Drug Development: Present Status And Future Prospects. Drug Discovery Today, 2019; 24**,** 773-780.
6. Shah, P., Kendall, F., Khozin, S., Goosen, R., Hu, J., Laramie, J., Ringel, M., Schork, N. Artificial Intelligence And Machine Learning In Clinical Development: A Translational Perspective. Npj Digital Medicine, 2019; 2**,** 69.
7. Saeed, H. & El Naqa, I. Artificial Intelligence In Clinical Trials. Machine And Deep Learning In Oncology, Medical Physics And Radiology. Springer. 2022.
8. Askin, S., Burkhalter, D., Calado, G. El Dakrouni, S. Artificial Intelligence Applied To Clinical Trials: Opportunities And Challenges. Health And Technology, 2023; 13**,** 203-213.
9. Benjamens, S., Dhunnoo, P. & Meskó, B. The State Of Artificial Intelligence-Based Fda-Approved Medical Devices And Algorithms: An Online Database. Npj Digital Medicine, 2020; 3**,** 118.

10. Shinozaki, A. Electronic Medical Records And Machine Learning In Approaches To Drug Development. Artificial Intelligence In Oncology Drug Discovery And Development. Intechopen. 2020.
11. Alam, M. N., Kaur, M., Kabir, M. S. 2023. Explainable Ai In Healthcare: Enhancing Transparency And Trust Upon Legal And Ethical Consideration. Int Res J Eng Technol, 2023; 10**,** 1-9.
12. Aliper, A., Kudrin R., Polykovskiy, D., Kamya, P., Tutubalina, E., Chen, S., Ren, F., Zhavoronkov, A. Prediction Of Clinical Trials Outcomes Based On Target Choice And Clinical Trial Design With Multi-Modal Artificial Intelligence. Clinical Pharmacology. Therapeutics, 2023; 114**,** 972-980.
13. Hinkson, I. V, Madej, B. Stahlberg, E. A. Accelerating Therapeutics For Opportunities In Medicine: A Paradigm Shift In Drug Discovery. Frontiers In Pharmacology, 2020; 11**,** 770.
14. Arowoogun, J.O., Babawarun, O., Chidi, R., Adeniyi, A.O. Okolo, C. A. A Comprehensive Review Of Data Analytics In Healthcare Management: Leveraging Big Data For Decision-Making. World Journal Of Advanced Research And Reviews, 2024; 21: 1810-1821.